Wir verwenden standardmäßig essenzielle Cookies (Anmeldung, deine gespeicherten Ziele/Stacks). Mit deiner Erlaubnis aktivieren wir außerdem datenschutzfreundliche Analytik (Vercel Web Analytics, anonyme Ladezeit-Metriken) und Fehler-Replay-Diagnostik (Sentry — DOM-Snapshots nur, wenn ein Fehler auftritt), damit wir Bugs schneller beheben können. Mehr über Cookies erfahren

Pip3.0

Piperlongumine – Forschung

Überwiegend Mechanismus / Beobachtung

7 begutachtete Studien

Was die Evidenz sagt

Überwiegend Mechanismus / Beobachtung

Die meisten Studien zu Piperlongumine sind mechanistisch oder beobachtend statt RCTs, die einen klinischen Effekt messen — betrachte die Ergebnisse als vorläufig.

Die meiste Evidenz stammt aus gemischt-qualitativen Studien, veröffentlicht 2013–2026.

Basierend auf 7 Studien

Konfidenz

Geringe Konfidenz

Nach Outcome

Cancer (preclinical)
Überwiegend Mechanismus / Beobachtung3 Studien
Safety profile
Überwiegend Mechanismus / Beobachtung3 Studien
Senescence & healthspan (preclinical)Ein natürliches Senolytikum, das seneszente Zellen in vitro beseitigt; keine Wirksamkeitsdaten am Menschen und schlechte orale Bioverfügbarkeit. · Nicht belegt (keine Humandaten)
Zu wenige bewertete Studien2 Studien

Stetige Forschung

2 Studien in den letzten 5 Jahren

201320192026

1Systematische Übersicht2026

By bridging ancient knowledge with modern innovations, this review highlights P. longum as a versatile candidate for integrative medicine and novel drug delivery strategies.

Bhatia A, Mehta J, Hashmi AR, Sekar M, Bandyopadhyay A, Pal T, Kumar BRP, Mat Rani NNI, Wong LS, Kumarasamy V. · Drug design, development and therapy (2026)

Furthermore, advances in nanotechnology including liposomes, cubosomes, and transgelosomes, have enhanced its solubility, bioavailability, and targeted pharmacological efficacy.
Industrial applications span nutraceuticals, phytopharmaceuticals, and green nanotechnology, underscoring its potential for commercialization.
Clinical and preclinical studies validate its efficacy and safety within therapeutic ranges.

Quelle ansehen

2In vitro2016

Piperlongumine preferentially killed senescent human WI-38 fibroblasts and is a novel lead for developing senolytic agents.

Wang, Chang, Liu, Zhang, Zhang, Zhang, Zhou, Zheng · Aging (2016)

Identified piperlongumine as a senolytic in the screen that produced ABT-263/navitoclax
Preferentially killed senescent human fibroblasts (radiation-, replicative-, and Ras-induced) by apoptosis
Synergized with navitoclax; early analogs improved potency/selectivity

Quelle ansehen

3In vitro2018

Piperlongumine bound and degraded OXR1 in senescent cells, identifying OXR1 as a novel senolytic target.

Zhang, Zhang, Liu, Wang, Chang, Zhang, Mackintosh, Tackett, He, Lv, Laberge, Campisi, Wang, Zheng, Zhou · Aging cell (2018)

Used a PL chemical probe + proteomics to find its target in senescent cells: oxidation-resistance protein 1 (OXR1)
OXR1 is upregulated in senescent cells; PL degraded it via the ubiquitin–proteasome system selectively in senescent cells
Knocking down OXR1 raised ROS and selectively induced apoptosis in senescent cells

Quelle ansehen

4Tierstudie2014

Piperlongumine selectively killed cancer cells by targeting the stress response to ROS and synergized with cisplatin in vitro and in vivo.

Roh, Kim, Park, Kim, Kwon, Lee · Oncotarget (2014)

Selectively killed head-and-neck cancer cells (regardless of p53 status) while sparing normal cells
Raised ROS; cytotoxicity was blocked by the antioxidant N-acetylcysteine, confirming the ROS mechanism
Inhibited tumor growth and synergized with cisplatin in mouse xenografts (in vivo)

Quelle ansehen

5Übersicht2020

Piperlongumine shows selective preclinical anticancer activity via ROS accumulation and glutathione depletion, with nanoformulation needed to overcome poor bioavailability.

Tripathi, Biswal · Pharmacological research (2020)

Comprehensive review of piperlongumine's anticancer mechanisms (ROS, glutathione depletion, PI3K/AKT/mTOR, NF-κB, STATs)
Documents selective cytotoxicity and chemo-/radio-sensitization across cancer types in vitro and in vivo
Explicitly notes poor solubility/bioavailability and the move to nanoformulations to address it

Quelle ansehen

6Übersicht2013

Piplartine is selectively cytotoxic to cancer cells via oxidative stress and inhibits tumor growth in mice, with chronic toxicology still needed before clinical trials.

Bezerra, Pessoa, de Moraes, Saker-Neto, Silveira, Costa-Lotufo · European journal of pharmaceutical sciences (2013)

Foundational review of piplartine/piperlongumine's chemistry and broad preclinical pharmacology
Anticancer activity (selective oxidative-stress-driven cytotoxicity, antitumor in mice) is its most promising property
Flags that chronic toxicology is still needed to support clinical trials — i.e. no human efficacy yet

Quelle ansehen

7Übersicht2024

Piperlongumine and its derivatives show preclinical anticancer promise, with ongoing work on analogs and delivery to overcome pharmacokinetic limitations.

Swain, Sahoo · Archiv der Pharmazie (2024)

Recent review of piperlongumine and synthetic derivatives as anticancer leads
Summarizes the parent compound's mechanism and the push toward derivatives/delivery systems
Underscores that translation is limited by pharmacokinetics — still no clinical efficacy

Quelle ansehen

In der Forschungsbibliothek ansehen

Piperlongumine – Forschung

Überwiegend Mechanismus / Beobachtung

From Ancient Spice to Advanced Science: Therapeutic, Nutraceutical and Nanotechnological Insights into the Fruits of Piper Longum Linn for Modern Drug Development

Discovery of piperlongumine as a potential novel lead for the development of senolytic agents.

Oxidation resistance 1 is a novel senolytic target.

Piperlongumine selectively kills cancer cells and increases cisplatin antitumor activity in head and neck cancer.

Piperlongumine, a potent anticancer phytotherapeutic: Perspectives on contemporary status and future possibilities as an anticancer agent.

Overview of the therapeutic potential of piplartine (piperlongumine).

Piperlongumine and its derivatives against cancer: A recent update and future prospective.